From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
AliasesCD160, BY55, NK1, NK28, CD160 molecule
External IDsMGI: 1860383 HomoloGene: 5122 GeneCards: CD160
Gene location (Human)
Chromosome 1 (human)
Chr.Chromosome 1 (human)[1]
Chromosome 1 (human)
Genomic location for CD160
Genomic location for CD160
Band1q21.1Start145,719,471 bp[1]
End145,739,288 bp[1]
RNA expression pattern
PBB GE CD160 207840 at fs.png
More reference expression data
RefSeq (mRNA)



RefSeq (protein)



Location (UCSC)Chr 1: 145.72 – 145.74 MbChr 3: 96.8 – 96.83 Mb
PubMed search[3][4]
View/Edit HumanView/Edit Mouse

CD160 antigen is a protein that in humans is encoded by the CD160 gene.[5][6][7]

CD160 is a 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.[7]

Clinical significance[edit]

CD160 is a ligand for HVEM, and considered a proposed immune checkpoint inhibitor with anti-cancer activity alongside with anti- PD-1 antibodies.[8] CD160 has also been proposed as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.[9]

Related gene problems[edit]

See also[edit]


  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000117281 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000038304 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:".
  4. ^ "Mouse PubMed Reference:".
  5. ^ Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD, Patel AT, Robertson MJ, Nadler LM, Freeman GJ (Oct 1998). "Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes". J Immunol. 161 (6): 2780–90. PMID 9743336.
  6. ^ Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, Roth P, Bolton W, Ogg G, Boumsell L, Bensussan A (Apr 1999). "Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells". J Immunol. 162 (3): 1223–6. PMID 9973372.
  7. ^ a b "Entrez Gene: CD160 CD160 molecule".
  8. ^ Stecher, Carmen; Battin, Claire; Leitner, Judith; Zettl, Markus; Grabmeier-Pfistershammer, Katharina; H?ller, Christoph; Zlabinger, Gerhard J.; Steinberger, Peter (22 May 2017). "PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells". Frontiers in Immunology. 8. doi:10.3389/fimmu.2017.00572.
  9. ^ Chabot, Sophie; Jabrane-Ferrat, Nabila; Bigot, Karine; Tabiasco, Julie; Provost, Alexandra; Golzio, Muriel; Noman, Muhammad Zaeem; Giustiniani, J?r?me; Bellard, Elisabeth; Brayer, St?phanie; Aguerre-Girr, Maryse; Meggetto, Fabienne; Giuriato, Sylvie; Malecaze, Fran?ois; Galiacy, St?phane; Ja?s, Jean-Philippe; Chose, Olivier; Kadouche, Jean; Chouaib, Salem; Teissi?, Justin; Abitbol, Marc; Bensussan, Armand; Le Bouteiller, Philippe (9 May 2011). "A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor". The Journal of Experimental Medicine. 208 (5): 973–986. doi:10.1084/jem.20100810. PMC 3092350.
  10. ^ Klopocki E, Schulze H, Strauss G, et al. (February 2007). "Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome". Am. J. Hum. Genet. 80 (2): 232–40. doi:10.1086/510919. PMC 1785342. PMID 17236129.

Further reading[edit]

External links[edit]